How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

907 results for

Acne Vulgaris Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color

The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03402893 Recruitment Status : Completed First Posted : January 18, 2018 Results First Posted : February 19, 2019 Last Update Posted : March 19, 2019 Sponsor: Derm Research, PLLC

2018 Clinical Trials

22. Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03650361 Recruitment Status : Active, not recruiting First Posted : August 28, 2018 Last Update Posted : January 24, 2019 Sponsor: Aleor Dermaceuticals Limited

2018 Clinical Trials

23. Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2018 Clinical Trials

24. Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2018 Clinical Trials

25. A Study Comparing Two Topicals in the Treatment of Acne Vulgaris

A Study Comparing Two Topicals in the Treatment of Acne Vulgaris A Study Comparing Two Topicals in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study Comparing Two (...) Topicals in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03743038 Recruitment Status : Recruiting First Posted : November 15, 2018 Last Update Posted : November 21, 2018 See Sponsor: Foamix

2018 Clinical Trials

26. Apelin12 in Acne Vulgaris

Apelin12 in Acne Vulgaris Apelin12 in Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Apelin12 in Acne Vulgaris The safety and scientific validity of this study is the responsibility (...) Description Go to Brief Summary: Acne vulgaris is a common chronic inflammatory disease of the pilosebaceous unit which is characterized by the formation of non-inflammatory open and closed comedones and inflammatory papules, pustules, nodules and cysts. It is a multifactorial disease that affects mostly adolescent population. Acne appears very early in puberty during the preteen years, often before menarche in girls. Because many adolescents have acne, it is difficult to predict which individuals

2018 Clinical Trials

27. Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris

Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation (...) of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03573518 Recruitment Status : Recruiting First Posted : June 29, 2018 Last Update Posted : January 18, 2019 See

2018 Clinical Trials

28. Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia

Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03626298 Recruitment Status : Completed First Posted : August 13, 2018 Last Update Posted : August 13, 2018 Sponsor: Rumah Sakit Pusat

2018 Clinical Trials

29. A Bioavailability Study of DFD-03 (Tazarotene, Lotion 0.1 % ) Compared to Tazorac® (Tazarotene), 0.1% in Patients With Moderate Acne Vulgaris

A Bioavailability Study of DFD-03 (Tazarotene, Lotion 0.1 % ) Compared to Tazorac® (Tazarotene), 0.1% in Patients With Moderate Acne Vulgaris A Bioavailability Study of DFD-03 (Tazarotene, Lotion 0.1 % ) Compared to Tazorac® (Tazarotene), 0.1% in Patients With Moderate Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Bioavailability Study of DFD-03 (Tazarotene, Lotion 0.1 % ) Compared to Tazorac® (Tazarotene), 0.1% in Patients With Moderate Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2018 Clinical Trials

30. A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris

A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

31. DMT310-001 Topical in the Treatment of Acne Vulgaris

DMT310-001 Topical in the Treatment of Acne Vulgaris DMT310-001 Topical in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. DMT310-001 Topical in the Treatment of Acne Vulgaris (...) Party): Dermata Therapeutics Study Details Study Description Go to Brief Summary: The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris. Condition or disease Intervention/treatment Phase Acne Vulgaris Drug: DMT310 Drug: Hydrogen Peroxide Drug: Placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated

2018 Clinical Trials

32. Thyroid Dysfunction in Female Patients With Acne Vulgaris: [ Relation to Other Variables ]

Thyroid Dysfunction in Female Patients With Acne Vulgaris: [ Relation to Other Variables ] Thyroid Dysfunction in Female Patients With Acne Vulgaris: [ Relation to Other Variables ] - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Thyroid Dysfunction in Female Patients With Acne Vulgaris: [ Relation to Other Variables ] The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03602534 Recruitment Status : Not yet recruiting First

2018 Clinical Trials

33. Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.

Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris. Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03752242 Recruitment Status : Recruiting First Posted : November 22, 2018 Last Update Posted

2018 Clinical Trials

34. To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03427554 Recruitment Status : Completed First Posted

2018 Clinical Trials

35. To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03433378 Recruitment Status : Completed First

2018 Clinical Trials

36. A Study of S6G5T 3 in the Treatment of Acne Vulgaris

A Study of S6G5T 3 in the Treatment of Acne Vulgaris A Study of S6G5T 3 in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of S6G5T 3 in the Treatment of Acne Vulgaris (...) provided by (Responsible Party): Sol-Gel Technologies, Ltd. Study Details Study Description Go to Brief Summary: To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in Patients with acne vulgaris Condition or disease Intervention/treatment Phase Acne Vulgaris Drug: S6G5T-3 Drug: S6G5T-8 Phase 3 Detailed Description: In this Phase 3, double blind, vehicle-controlled study, patients will be admitted into this multi-center, double blind, randomized, vehicle

2018 Clinical Trials

37. A Study of S6G5T-3 in the Treatment of Acne Vulgaris

A Study of S6G5T-3 in the Treatment of Acne Vulgaris A Study of S6G5T-3 in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of S6G5T-3 in the Treatment of Acne Vulgaris (...) provided by (Responsible Party): Sol-Gel Technologies, Ltd. Study Details Study Description Go to Brief Summary: To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in Patients with acne vulgaris Condition or disease Intervention/treatment Phase Acne Vulgaris Drug: S6G5T-3 Drug: S6G5T-8 Phase 3 Detailed Description: In this Phase 3, double blind, vehicle-controlled study, patients will be admitted into this multi-center, double blind, randomized, vehicle

2018 Clinical Trials

38. Effectiveness of topical or oral pharmacological and physical interventions in treatment resistant acne vulgaris

Effectiveness of topical or oral pharmacological and physical interventions in treatment resistant acne vulgaris Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated (...) as the fixed-effect model. For further details, see the and to pre-clinical meta-analysis. Example: Because of the exploratory nature of animal studies, a random effects model will be used to account for anticipated heterogeneity. ">Effect models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than one experimental group, we

2020 PROSPERO

39. Effectiveness of topical or oral pharmacological and physical interventions in the treatment of acne vulgaris: a systematic review using network and pairwise meta-analysis

Effectiveness of topical or oral pharmacological and physical interventions in the treatment of acne vulgaris: a systematic review using network and pairwise meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability (...) will yield the same results as the fixed-effect model. For further details, see the and to pre-clinical meta-analysis. Example: Because of the exploratory nature of animal studies, a random effects model will be used to account for anticipated heterogeneity. ">Effect models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than

2020 PROSPERO

40. Effectiveness of topical or oral pharmacological and physical interventions in the treatment of acne vulgaris in people with polycystic ovary syndrome

Effectiveness of topical or oral pharmacological and physical interventions in the treatment of acne vulgaris in people with polycystic ovary syndrome Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) will yield the same results as the fixed-effect model. For further details, see the and to pre-clinical meta-analysis. Example: Because of the exploratory nature of animal studies, a random effects model will be used to account for anticipated heterogeneity. ">Effect models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than

2020 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>